Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Bendamustine Hydrochloride"" wg kryterium: Temat


Tytuł :
Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report.
Autorzy :
Imoto N; Division of Hematology and Oncology, Toyohashi Municipal Hospital, Aichi.
Koyama D; Division of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Sugiura I; Division of Hematology and Oncology, Toyohashi Municipal Hospital, Aichi.
Kurahashi S; Division of Hematology and Oncology, Toyohashi Municipal Hospital, Aichi.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Feb 05; Vol. 100 (5), pp. e24457.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Bendamustine Hydrochloride/*therapeutic use
Leukemia, Hairy Cell/*drug therapy
Rituximab/*therapeutic use
Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols ; Bendamustine Hydrochloride/administration & dosage ; Humans ; Male ; Middle Aged ; Rituximab/administration & dosage
Czasopismo naukowe
Tytuł :
Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.
Autorzy :
Lucijanic M; Hematology Department, University hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
Jaksic O; Hematology Department, University hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia. .; School of Medicine, University of Zagreb, Zagreb, Croatia. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Sep; Vol. 99 (9), pp. 2191-2192. Date of Electronic Publication: 2020 Jun 17.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bendamustine Hydrochloride/*adverse effects
Leukoencephalopathy, Progressive Multifocal/*chemically induced
Lymphoma, Follicular/*therapy
Rituximab/*adverse effects
Adrenal Cortex Hormones/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/administration & dosage ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Fatal Outcome ; Female ; Humans ; Immunoglobulins, Intravenous/therapeutic use ; Leukoencephalopathy, Progressive Multifocal/complications ; Leukoencephalopathy, Progressive Multifocal/diagnostic imaging ; Leukoencephalopathy, Progressive Multifocal/therapy ; Lymphoma, Follicular/complications ; Lymphopenia/chemically induced ; Magnetic Resonance Imaging ; Maintenance Chemotherapy/adverse effects ; Middle Aged ; Plasmapheresis ; Prednisone/administration & dosage ; Recurrence ; Rituximab/administration & dosage ; Vincristine/administration & dosage
SCR Protocol :
CHOP protocol
Raport
Tytuł :
Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.
Autorzy :
Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Li X; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Guo W; Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, P.R. China.
Li F; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Huang J; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Huang X; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Pan J; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Huang S; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Ye W; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Ling Q; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Pokaż więcej
Źródło :
Oncology reports [Oncol Rep] 2020 Jul; Vol. 44 (1), pp. 273-282. Date of Electronic Publication: 2020 Apr 22.
Typ publikacji :
Journal Article
MeSH Terms :
Bendamustine Hydrochloride/*administration & dosage
Daunorubicin/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Vorinostat/*administration & dosage
Animals ; Bendamustine Hydrochloride/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; DNA Damage ; Daunorubicin/pharmacology ; Drug Synergism ; Female ; HL-60 Cells ; Humans ; Leukemia, Myeloid, Acute/genetics ; Mice ; Vorinostat/pharmacology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Is bendamustine plus rituximab a suitable option for rituximab-refractory duodenal-type follicular lymphoma?
Autorzy :
Cencini E; Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Italy.
Fabbri A; Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Italy.
Mecacci B; Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Italy.
Bocchia M; Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Italy.
Pokaż więcej
Źródło :
Acta gastro-enterologica Belgica [Acta Gastroenterol Belg] 2020 Jul-Sep; Vol. 83 (3), pp. 493.
Typ publikacji :
Letter
MeSH Terms :
Bendamustine Hydrochloride*/therapeutic use
Lymphoma, Follicular*/drug therapy
Rituximab*/therapeutic use
Humans
Opinia redakcyjna
Tytuł :
Isolated intracardiac recurrence of diffuse large B-cell lymphoma successfully treated with rituximab and bendamustine chemotherapy regimen.
Autorzy :
Chang CH; Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Lin CS; Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Ho CL; Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Pokaż więcej
Źródło :
Journal of postgraduate medicine [J Postgrad Med] 2020 Jul-Sep; Vol. 66 (3), pp. 176-177.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Bendamustine Hydrochloride/*therapeutic use
Betamethasone/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Rituximab/*therapeutic use
Administration, Intravenous ; Aged ; Bendamustine Hydrochloride/administration & dosage ; Betamethasone/administration & dosage ; Humans ; Lymphoma, Large B-Cell, Diffuse/pathology ; Rituximab/administration & dosage ; Treatment Outcome
Raport
Tytuł :
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
Autorzy :
D'Alò F; Area of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; Università Cattolica del Sacro Cuore, Rome, Italy.
Malafronte R; Area of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Piludu F; Unit of Radiology and Neuroradiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Bellesi S; Area of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Cuccaro A; Area of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Maiolo E; Area of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Modoni A; Unit of Neurology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Leccisotti L; Unit of Nuclear Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Macis G; Università Cattolica del Sacro Cuore, Rome, Italy.; Unit of Radiology and Neuroradiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Mores N; Università Cattolica del Sacro Cuore, Rome, Italy.; Unit of Pharmacovigilance, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
De Stefano V; Area of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; Università Cattolica del Sacro Cuore, Rome, Italy.
Hohaus S; Area of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; Università Cattolica del Sacro Cuore, Rome, Italy.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (4), pp. e140-e144. Date of Electronic Publication: 2020 Mar 09.
Typ publikacji :
Letter
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bendamustine Hydrochloride/*therapeutic use
Leukoencephalopathy, Progressive Multifocal/*etiology
Lymphoma, Follicular/*complications
Rituximab/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bendamustine Hydrochloride/pharmacology ; Female ; Humans ; Lymphoma, Follicular/drug therapy ; Male ; Middle Aged ; Retrospective Studies ; Rituximab/pharmacology
Opinia redakcyjna
Tytuł :
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
Autorzy :
McCulloch R; Department of Haematology, University Hospitals Plymouth NHS Trust, Plymouth, UK.
Visco C; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Eyre TA; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Frewin R; Department of Haematology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
Phillips N; Department of Haematology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
Tucker DL; Department of Haematology, Royal Cornwall Hospitals NHS Trust, Truro, UK.
Quaglia FM; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
McMillan A; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Lambert J; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Crosbie N; Department of Haematology, University Hospitals Plymouth NHS Trust, Plymouth, UK.
Rule S; Department of Haematology, University Hospitals Plymouth NHS Trust, Plymouth, UK.; Peninsula Medical School, University of Plymouth, Plymouth, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (4), pp. 684-688. Date of Electronic Publication: 2020 Feb 03.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bendamustine Hydrochloride/*therapeutic use
Cytarabine/*therapeutic use
Lymphoma, Mantle-Cell/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Rituximab/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bendamustine Hydrochloride/pharmacology ; Cytarabine/pharmacology ; Female ; Humans ; Lymphoma, Mantle-Cell/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Rituximab/pharmacology
Czasopismo naukowe
Tytuł :
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
Autorzy :
LaCasce AS; Dana-Farber Cancer Institute, Boston, MA, USA.
Bociek RG; University of Nebraska Medical Center, Omaha, NE, USA.
Sawas A; Columbia University Medical Center, New York, NY, USA.
Caimi P; University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Agura E; Charles A. Sammons Cancer Center, Dallas, TX, USA.
Matous J; Colorado Blood Cancer Institute, Denver, CO, USA.
Ansell SM; Mayo Clinic, Rochester, MN, USA.
Crosswell HE; St. Francis Hospital, Greenville, SC, USA.
Islas-Ohlmayer M; The Jewish Hospital-Mercy Health, Cincinnati, OH, USA.
Behler C; Pacific Hematology Oncology Associates, San Francisco, CA, USA.
Cheung E; The Oncology Institute of Hope & Innovation, Whittier, CA, USA.
Forero-Torres A; University of Alabama at Birmingham, Birmingham, AL, USA.
Vose J; University of Nebraska Medical Center, Omaha, NE, USA.
O'Connor OA; Columbia University Medical Center, New York, NY, USA.
Josephson N; Seattle Genetics, Inc, Bothell, WA, USA.
Wang Y; Seattle Genetics, Inc, Bothell, WA, USA.
Advani R; Stanford Cancer Institute, Stanford, CA, USA.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (3), pp. e86-e90. Date of Electronic Publication: 2020 Feb 12.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Bendamustine Hydrochloride/*therapeutic use
Brentuximab Vedotin/*therapeutic use
Hodgkin Disease/*drug therapy
Salvage Therapy/*methods
Antineoplastic Agents, Immunological/pharmacology ; Bendamustine Hydrochloride/pharmacology ; Brentuximab Vedotin/pharmacology ; Female ; Hodgkin Disease/mortality ; Humans ; Male ; Survival Analysis ; Time Factors ; Treatment Outcome
Raport
Tytuł :
Consolidation with Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.
Autorzy :
Miura K; Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Tsujimura H; Division of Medical Oncology, Chiba Cancer Center, Chiba, Japan.
Masaki Y; Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Iino M; Department of Medical Oncology, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Takizawa J; Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.
Maeda Y; Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yamamoto K; Department of Hematology, Okayama City Hospital, Okayama, Japan.
Tamura S; Department of Hematology/Oncology, Kinan Hospital, Tanabe, Japan.
Yoshida A; Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan.
Yagi H; Department of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan.
Yoshida I; Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Kitazume K; Department of Hematology, Showa General Hospital, Tokyo, Japan.
Masunari T; Department of Infectious Diseases, Chugoku Central Hospital, Fukuyama, Japan.
Choi I; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kakinoki Y; Department of Hematology, Asahikawa City Hospital, Asahikawa, Japan.
Suzuki R; Department of Oncology/Hematology, Innovative Cancer Center, Shimane University Hospital, Izumo, Japan.
Yoshino T; Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Nakamura S; Department of Pathology and Biological Response, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hatta Y; Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Yoshida T; Member, Society of Lymphoma Treatment in Japan, Kashihara, Japan.
Kanno M; Oncology Center, Nara Medical University Hospital, Kashihara, Japan.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Feb; Vol. 39 (1), pp. 51-59. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Consolidation Chemotherapy*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Lymphoma, Follicular/*drug therapy
Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/adverse effects ; Female ; Humans ; Lymphoma, Follicular/metabolism ; Lymphoma, Follicular/pathology ; Male ; Middle Aged ; Recurrence ; Rituximab/administration & dosage ; Rituximab/adverse effects
Czasopismo naukowe
Tytuł :
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Autorzy :
Kabadi SM; Epidemiology and Real-World Evidence, AstraZeneca, Oncology, Gaithersburg, MD, U.S.A.
Byfield SD; Health Economics and Outcomes Research, Optum, Eden Prairie, MN, U.S.A.; .
LE L; Health Economics and Outcomes Research, Optum, Eden Prairie, MN, U.S.A.
Olufade T; Health Economics and Outcomes Research, AstraZeneca, Gaithersburg, MD, U.S.A.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Feb; Vol. 41 (2), pp. 927-936.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Chemical and Drug Induced Liver Injury/*economics
Lymphoma, Mantle-Cell/*drug therapy
Renal Insufficiency/*economics
Stroke/*economics
Adenine/adverse effects ; Adenine/analogs & derivatives ; Adenine/economics ; Adenine/therapeutic use ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/economics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bendamustine Hydrochloride/adverse effects ; Bendamustine Hydrochloride/economics ; Bendamustine Hydrochloride/therapeutic use ; Cyclophosphamide/adverse effects ; Cyclophosphamide/economics ; Cyclophosphamide/therapeutic use ; Doxorubicin/adverse effects ; Doxorubicin/economics ; Doxorubicin/therapeutic use ; Female ; Health Care Costs ; Humans ; Male ; Middle Aged ; Piperidines/adverse effects ; Piperidines/economics ; Piperidines/therapeutic use ; Prednisone/adverse effects ; Prednisone/economics ; Prednisone/therapeutic use ; Renal Insufficiency/chemically induced ; Retrospective Studies ; Rituximab/adverse effects ; Rituximab/economics ; Rituximab/therapeutic use ; Stroke/chemically induced ; Vincristine/adverse effects ; Vincristine/economics ; Vincristine/therapeutic use
Czasopismo naukowe
Tytuł :
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas.
Autorzy :
Vannata B; Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
Vanazzi A; Division of Clinical Hemato-Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Negri M; Division of Clinical Hemato-Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Liptrott SJ; Division of Clinical Hemato-Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Bartosek AA; Nerviano Medical Sciences S.r.l, Nerviano, Milan, Italy.
Miani M; Nerviano Medical Sciences S.r.l, Nerviano, Milan, Italy.
Di Sanzo A; Nerviano Medical Sciences S.r.l, Nerviano, Milan, Italy.
Cavalli F; Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.; Faculty of Biomedical Sciences, Institute of Oncology Research (IOR), Bellinzona, Switzerland.
Zucca E; Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.; Faculty of Biomedical Sciences, Institute of Oncology Research (IOR), Bellinzona, Switzerland.
Stathis A; Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera italiana (USI), Lugano, Switzerland.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Feb; Vol. 39 (1), pp. 60-65. Date of Electronic Publication: 2020 Nov 06.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Lymphoma, B-Cell, Marginal Zone/*drug therapy
Lymphoma, B-Cell, Marginal Zone/*mortality
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/adverse effects ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Recurrence ; Survival Rate
Czasopismo naukowe
Tytuł :
Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia.
Autorzy :
Gao H; College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Lou S; College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Hong H; College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Ge Q; Hangzhou Tinuo Pharmaceutical Co., Ltd., Hangzhou 310053, China.
Zhao H; College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Pokaż więcej
Źródło :
BioMed research international [Biomed Res Int] 2020 Feb 14; Vol. 2020, pp. 1520651. Date of Electronic Publication: 2020 Feb 14 (Print Publication: 2020).
Typ publikacji :
Journal Article
MeSH Terms :
Bendamustine Hydrochloride*/analogs & derivatives
Bendamustine Hydrochloride*/pharmacology
Antineoplastic Agents/*pharmacology
Autophagy/*drug effects
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*metabolism
Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; DNA Damage/drug effects ; Humans ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Extended follow-up of CD4 T cell recovery kinetics in a large cohort of patients with B-cell lymphoproliferative disease treated with rituximab-bendamustine.
Autorzy :
Gaiolla R; Clinical Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.; Haematology Division, Clinical Hospital of Botucatu Medical School-HCFMB, Botucatu, Brazil.
Hartley S; Clinical Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Beech A; Clinical Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Knight H; Clinical Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Smith D; Clinical Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Bishton M; Clinical Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Fox CP; Clinical Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.; School of Medicine, University of Nottingham, Nottingham, UK.
Martinez-Calle N; Clinical Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Feb; Vol. 39 (1), pp. 137-140. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji :
Letter
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
CD4-Positive T-Lymphocytes/*metabolism
Leukemia, Lymphocytic, Chronic, B-Cell/*blood
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Recovery of Function/*drug effects
Adult ; Aged ; Aged, 80 and over ; Bendamustine Hydrochloride/administration & dosage ; CD4 Lymphocyte Count ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Rituximab/administration & dosage
Opinia redakcyjna
Tytuł :
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
Autorzy :
Cohen JB; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Wei L; Center for Biostatistics, The Ohio State University, Columbus, Ohio.
Maddocks KJ; Division of Hematology, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Christian B; Division of Hematology, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Heffner LT; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Langston AA; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Lechowicz MJ; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Porcu P; Division of Hematology, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Flowers CR; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Devine SM; Division of Hematology, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Blum KA; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.; Division of Hematology, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Mar 15; Vol. 126 (6), pp. 1235-1242. Date of Electronic Publication: 2019 Dec 10.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bendamustine Hydrochloride/*administration & dosage
Deoxycytidine/*analogs & derivatives
Hodgkin Disease/*drug therapy
Salvage Therapy/*methods
Adult ; Aged ; Antibiotics, Antineoplastic/administration & dosage ; Antibiotics, Antineoplastic/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/adverse effects ; Bleomycin/administration & dosage ; Bleomycin/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Female ; Humans ; Male ; Middle Aged ; Progression-Free Survival ; Recurrence ; Young Adult
Czasopismo naukowe
Tytuł :
High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
Autorzy :
Prediletto I; Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland.
Farag SA; Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland.
Bacher U; Department of Hematology and Central Hematology Laboratory, University Hospital and University of Bern, Bern, Switzerland.
Jeker B; Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland.
Mansouri Taleghani B; Department of Hematology and Central Hematology Laboratory, University Hospital and University of Bern, Bern, Switzerland.
Brégy R; Department of Pharmacy, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Zander T; Department of Oncology, Kantonsspital, Lucerne, Switzerland.
Betticher D; Department of Oncology, Kantonsspital, Fribourg, Switzerland.
Egger T; Department of Oncology, Bürgerspital, Solothurn, Switzerland.
Novak U; Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland.
Pabst T; Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland. .
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2019 Dec; Vol. 54 (12), pp. 1923-1925. Date of Electronic Publication: 2019 Mar 19.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents, Alkylating/*adverse effects
Bendamustine Hydrochloride/*adverse effects
Kidney/*drug effects
Lymphoma/*drug therapy
Multiple Myeloma/*drug therapy
Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Agents, Alkylating/therapeutic use ; Bendamustine Hydrochloride/pharmacology ; Bendamustine Hydrochloride/therapeutic use ; Female ; Humans ; Incidence ; Male
Raport
Tytuł :
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Autorzy :
Zinzani PL; Institute of Hematology 'L. e A. Seràgnoli,' University of Bologna, Bologna, Italy.
Flinn IW; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
Yuen SLS; Department of Haematology, Calvary Mater Newcastle, Waratah, NSW, Australia.
Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Rusconi C; Division of Hematology, Niguarda Hospital, Milan, Italy.
Fleury I; Department of Hematology, Maisonneuve-Rosemont Hospital and University of Montreal, Montreal, QC, Canada.
Le Dû K; Hematology Department, Clinique Victor Hugo, Le Mans, France.
Arthur C; Department of Haematology, Royal North Shore Hospital, St Leonards, NSW, Australia.
Pro B; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL.
Gritti G; Hematology and BMT Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Crump M; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Petrich A; AbbVie, North Chicago, IL.
Samineni D; Genentech, Inc., South San Francisco, CA.
Sinha A; Roche Products Limited, Welwyn Garden City, United Kingdom.
Punnoose EA; Genentech, Inc., South San Francisco, CA.
Szafer-Glusman E; Genentech, Inc., South San Francisco, CA.
Spielewoy N; F. Hoffmann-La Roche Ltd, Basel, Switzerland; and.
Mobasher M; Genentech, Inc., South San Francisco, CA.
Humphrey K; Roche Products Limited, Welwyn Garden City, United Kingdom.
Kornacker M; F. Hoffmann-La Roche Ltd, Basel, Switzerland; and.
Hiddemann W; Department of Medicine III, University of Munich, Munich, Germany.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Dec 03; Vol. 136 (23), pp. 2628-2637.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/administration & dosage
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Lymphoma, Follicular/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Female ; Humans ; Lymphoma, Follicular/mortality ; Male ; Middle Aged ; Recurrence ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects
Czasopismo naukowe
Tytuł :
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Autorzy :
Ramos CA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.; Department of Medicine, Baylor College of Medicine, Houston, TX.
Grover NS; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Beaven AW; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Lulla PD; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.; Department of Medicine, Baylor College of Medicine, Houston, TX.
Wu MF; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.; Biostatistics Shared Resource, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX.
Ivanova A; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Wang T; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.; Biostatistics Shared Resource, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX.
Shea TC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Rooney CM; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.; Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Department of Pathology and Immunology, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX.
Dittus C; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Park SI; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Gee AP; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.; Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Eldridge PW; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
McKay KL; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Mehta B; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.
Cheng CJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Buchanan FB; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Grilley BJ; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.
Morrison K; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Brenner MK; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.; Department of Medicine, Baylor College of Medicine, Houston, TX.; Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Serody JS; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Immunology and Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Dotti G; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Immunology and Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Heslop HE; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Dan L. Duncan Cancer, Baylor College of Medicine; Houston, TX.; Department of Medicine, Baylor College of Medicine, Houston, TX.; Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Savoldo B; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Immunology and Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Nov 10; Vol. 38 (32), pp. 3794-3804. Date of Electronic Publication: 2020 Jul 23.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Hodgkin Disease/*therapy
Immunotherapy, Adoptive/*methods
Ki-1 Antigen/*immunology
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/therapeutic use ; Combined Modality Therapy ; Cyclophosphamide/administration & dosage ; Epitopes ; Female ; Hodgkin Disease/drug therapy ; Hodgkin Disease/immunology ; Humans ; Immunotherapy, Adoptive/adverse effects ; Ki-1 Antigen/antagonists & inhibitors ; Lymphocyte Depletion ; Male ; Middle Aged ; Stem Cell Transplantation/methods ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives ; Young Adult
Czasopismo naukowe
Tytuł :
Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.
Autorzy :
Dumont M; Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Ram-Wolff C; Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Roelens M; Immunology (Inserm U1160), Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Brice P; Hemato-oncology, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Peffault de Latour R; Departments of Hematology-Bone Marrow Transplantation, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Battistella M; Departments of Pathology (Inserm U976), Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Madelaine I; Pharmacy, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Delyon J; Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Herms F; Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Bouaziz JD; Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Moins-Teisserenc H; Immunology (Inserm U1160), Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Lebbé C; Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Bagot M; Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
de Masson A; Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France.
Pokaż więcej
Źródło :
The British journal of dermatology [Br J Dermatol] 2019 Dec; Vol. 181 (6), pp. 1315-1317. Date of Electronic Publication: 2019 Aug 22.
Typ publikacji :
Letter
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bendamustine Hydrochloride/*administration & dosage
Brentuximab Vedotin/*administration & dosage
Lymphoma, T-Cell, Cutaneous/*drug therapy
Skin Neoplasms/*drug therapy
Acute Kidney Injury/chemically induced ; Acute Kidney Injury/diagnosis ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/adverse effects ; Brentuximab Vedotin/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Lymphoma, T-Cell, Cutaneous/diagnosis ; Lymphoma, T-Cell, Cutaneous/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Pneumonia, Pneumocystis/chemically induced ; Pneumonia, Pneumocystis/diagnosis ; Pneumonia, Pneumocystis/immunology ; Severity of Illness Index ; Skin/drug effects ; Skin/pathology ; Skin Neoplasms/diagnosis ; Skin Neoplasms/pathology ; Treatment Outcome
Opinia redakcyjna
Tytuł :
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.
Autorzy :
Gomez-Arteaga A; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA. .
Mark TM; Department of Medicine, Division of Hematology, University of Colorado - Anschutz Medical Campus, New York, NY, USA.
Guarneri D; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Christos PJ; Department of Healthcare Policy & Research, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Gergis U; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Greenberg JD; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Hsu J; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Mayer SA; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Niesvizky R; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Pearse RN; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Phillips AA; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Rossi A; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Coleman M; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
van Besien K; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Shore TB; Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2019 Dec; Vol. 54 (12), pp. 2027-2038. Date of Electronic Publication: 2019 Jun 12.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bendamustine Hydrochloride/*therapeutic use
Melphalan/*therapeutic use
Multiple Myeloma/*drug therapy
Transplantation, Autologous/*methods
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bendamustine Hydrochloride/pharmacology ; Female ; Humans ; Male ; Melphalan/pharmacology ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł :
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Autorzy :
Peñalver FJ; Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
Márquez JA; Hospital de Basurto, Vizcaya, Spain.
Durán S; Complejo Hospitalario de Jaén, Jaén, Spain.
Giraldo P; Hospital Universitario Miguel Servet, Zaragoza, Spain.
Martín A; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.
Montalbán C; Hospital Universitario Ramón y Cajal, Madrid, Spain.
Sancho JM; ICO-IJC Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
Ramírez MJ; Hospital de Especialidades de Jerez de la Frontera, Cádiz, Spain.
Terol MJ; Hospital Clínico Universitario de Valencia, Valencia, Spain.
Capote FJ; Hospital Puerta del Mar, Cádiz, Spain.
Gutiérrez A; Hospital Universitario Son Dureta, Palma de Mallorca, Spain.
Sánchez B; Hospital del Mar, Barcelona, Spain.
López A; Hospital Vall d'Hebron, Barcelona, Spain.
Salar A; Hospital del Mar, Barcelona, Spain.
Rodríguez-Caravaca G; Universidad Rey Juan Carlos, Madrid, Spain.
Canales M; Hospital Universitario La Paz, Madrid, Spain.
Caballero MD; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.
Pokaż więcej
Corporate Authors :
GELTAMO (The Spanish Lymphoma Cooperative Group)
Źródło :
Cancer medicine [Cancer Med] 2019 Nov; Vol. 8 (16), pp. 6955-6966. Date of Electronic Publication: 2019 Oct 01.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Salvage Therapy*
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bendamustine Hydrochloride/*therapeutic use
Dexamethasone/*therapeutic use
Lymphoma, Follicular/*drug therapy
Mitoxantrone/*therapeutic use
Rituximab/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/adverse effects ; Dexamethasone/adverse effects ; Drug Resistance, Neoplasm ; Female ; Humans ; Immunotherapy ; Lymphoma, Follicular/mortality ; Male ; Middle Aged ; Mitoxantrone/adverse effects ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/mortality ; Progression-Free Survival ; Rituximab/adverse effects
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies